dMMR indicates DNA mismatch repair deficient; ECOG, Eastern Cooperative Oncology Group; MSI-H, microsatellite-instability high; MSS, microsatellite stable; pMMR, DNA mismatch repair proficient. A, Overall survival; and B, overall survival by subgroups for patients treated with durvalumab and tremelimumab and best supportive care vs best supportive care alone.
eTable 1. Molecular characteristics from baseline cfDNA analysis
eFigure 1. Hazard ratios for overall survivals (A) and the corresponding P value (B) with different TMB cut points
eFigure 2. Overall Survival in patients with baseline TMB < 28 (A) and TMB ≥ 28 (B)
eFigure 3. Progression-free survival
Data Sharing Statement.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chen EX, Jonker DJ, Loree JM, et al. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. Published online May 07, 2020. doi:10.1001/jamaoncol.2020.0910
Can combined immune checkpoint inhibition improve overall survival (OS) in patients with advanced refractory colorectal cancer (CRC)?
In this randomized phase 2 study with 180 patients randomized in a 2:1 ratio to tremelimumab and durvalumab plus best supportive care or best supportive care alone, the median OS was 6.6 months for durvalumab and tremelimumab and 4.1 months for best supportive care; correlative analysis revealed that patients with plasma tumor mutation burden (TMB) of 28 or more variants per megabase had the greatest OS benefit.
Combined immune checkpoint inhibition may prolong OS in patients with advanced refractory CRC.
Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H).
To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibition improved patient survival in metastatic refractory CRC.
Design, Setting, and Participants
A randomized phase 2 study was conducted in 27 cancer centers across Canada between August 2016 and June 2017, and data were analyzed on October 18, 2018. Eligible patients had histologically confirmed adenocarcinoma of the colon or rectum; received all available standard systemic therapies (fluoropyrimidines, oxaliplatin, irinotecan, and bevacizumab if appropriate; cetuximab or panitumumab if RAS wild-type tumors; regorafenib if available); were aged 18 years or older; had adequate organ function; had Eastern Cooperative Oncology Group performance status of 0 or 1, and measurable disease.
We randomly assigned patients to receive either 75 mg of tremelimumab every 28 days for the first 4 cycles plus 1500 mg durvalumab every 28 days, or best supportive care alone (BSC) in a 2:1 ratio.
Main Outcomes and Measures
The primary end point was overall survival (OS) and a 2-sided P<.10 was considered statistically significant. Circulating cell-free DNA from baseline plasma was used to determine microsatellite instability (MSI) and tumor mutation burden (TMB).
Of 180 patients enrolled (121 men [67.2%] and 59 women [32.8%]; median [range] age, 65 [36-87] years), 179 were treated. With a median follow-up of 15.2 months, the median OS was 6.6 months for durvalumab and tremelimumab and 4.1 months for BSC (hazard ratio [HR], 0.72; 90% CI, 0.54-0.97; P = .07). Progression-free survival was 1.8 months and 1.9 months respectively (HR, 1.01; 90% CI, 0.76-1.34). Grade 3 or 4 adverse events were significantly more frequent with immunotherapy (75 [64%] patients in the treatment group had at least 1 grade 3 or higher adverse event vs 12 [20%] in the BSC group). Circulating cell-free DNA analysis was successful in 168 of 169 patients with available samples. In patients who were microsatellite stable (MSS), OS was significantly improved with durvalumab and tremelimumab (HR, 0.66; 90% CI, 0.49-0.89; P = .02). Patients who were MSS with plasma TMB of 28 variants per megabase or more (21% of MSS patients) had the greatest OS benefit (HR, 0.34; 90% CI, 0.18-0.63; P = .004).
Conclusions and Relevance
This phase 2 study suggests that combined immune checkpoint inhibition with durvalumab plus tremelimumab may be associated with prolonged OS in patients with advanced refractory CRC. Elevated plasma TMB may select patients most likely to benefit from durvalumab and tremelimumab. Further confirmation studies are warranted.
ClinicalTrials.gov Identifier: NCT02870920
Colorectal cancer is the second leading cause of cancer death worldwide, accounting for approximately 880 000 deaths in 2018.1 According to the American Cancer Society, there are expected to be 51 020 deaths from advanced colorectal cancer in 2019 in the United States.2 For most patients with advanced colorectal cancer, systemic therapy is the main treatment modality with median overall survival (OS) approaching 30 months in clinical trials.3,4
Despite recent approval of agents such as trifluridine/tipiracil (TAS-102) and regorafenib, outcomes for patients with advanced colorectal cancer remain poor and new treatments are needed.5,6 Monoclonal antibodies (mAb) against programmed death receptor-1 (PD-1), pembrolizumab and nivolumab, have shown considerable activity in patients with advanced colorectal cancer with DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) tumors.7-9 However, single-agent immune checkpoint inhibitors have not shown meaningful activities in DNA mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer. Quiz Ref IDRecently, combined blockade with nivolumab and the cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) antibody, ipilimumab, demonstrated additional benefit compared with nivolumab alone in patients with dMMR/MSI-H tumors.10
Durvalumab (Imfinzi, AstraZeneca) is a selective, high-affinity human IgG1 mAb against programmed death ligand 1 (PD-L1), whereas tremelimumab is a selective human IgG2 mAb against CTLA-4. Durvalumab and tremelimumab can be combined with manageable adverse events.11 We hypothesized that a combined blockade of PD-L1 and CTLA-4 would provide greater anticancer activity and conducted a randomized phase 2 clinical trial to evaluate the efficacy of durvalumab and tremelimumab in patients with advanced refractory colorectal cancer.
The trial protocol is available in Supplement 1. Eligible patients (121 men [67.2%] and 59 women [32.8%]; median [range] age, 65 [36-87] years) gave written informed consent; had histologically confirmed adenocarcinoma of the colon or rectum; received all available standard systemic therapies (fluoropyrimidines, oxaliplatin, irinotecan, and bevacizumab if appropriate; cetuximab or panitumumab if RAS wild-type; regorafenib if available); were aged 18 years or older; had adequate hematologic, renal, and liver function; had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1).12 Patients were excluded if they received prior mAbs targeting PD-1, PD-L1, or CTLA-4, or had a history of autoimmune disorders or severe immune-mediated toxic effects.
The study was approved by the institutional review board of each participating center, conducted according to the principles of the Declaration of Helsinki, complied with all applicable regulations, and was registered on ClinicalTrials.gov (NCT02870920).
Patients were randomized, in a 2:1 ratio, to receive 75 mg of tremelimumab intravenously every 4 weeks for the initial 4 cycles only, durvalumab 1500 mg of intravenously every 4 weeks, and best supportive care (BSC) (the treatment group) or BSC alone. The randomization was dynamically balanced by ECOG performance status (0 or 1), and the site of primary tumor using the method of minimization. Randomization was performed centrally by the Canadian Cancer Trials Group (CCTG) central office. The study was open label, and investigators and patients were not blinded to treatment assignments. No crossover was allowed between treatment groups.
Patients were evaluated clinically every 4 weeks while on study treatments, and every 12 weeks after disease progression. Radiological assessments with computed tomographic images were performed every 8 weeks until progression. Treatments continued until there was radiological or clinical evidence of disease progression, intolerable toxic effects, withdrawal of consent, or death. Adverse events were collected and classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0.13
Blood samples for circulating cell-free DNA (cfDNA) were collected prior to study therapy, at 8 weeks, and at the time of disease progression. Baseline samples were analyzed using the GuardantOMNI next generation sequencing 2.15 Mb, 500-gene panel (Guardant Health, Inc) to identify single nucleotide variants (SNVs), indels, fusions, copy number amplifications, MSI-high status, and tumor mutation burden (TMB).14 Plasma TMB was reported as variations per megabase (vts/Mb) by the GuardantOMNI algorithm, which includes all somatic synonymous and nonsynonymous SNVs and indels excluding germline, clonal hematopoiesis of indeterminate potential (CHIP), driver and resistance variations with statistical adjustment for sample-specific tumor shedding and molecular coverage. Validation of plasma TMB and MSI have been previously described.15,16
Quality of life was assessed using EORTC QLQ-C30 at baseline, 4, 8, 12, 16, 24 weeks, then every 12 weeks until deterioration to ECOG PS 4 or death.17
The primary end point was OS, defined as the time from randomization to death from any cause. Secondary end points included progression-free survival ([PFS], the time from randomization to the first objective documentation of disease progression or death from any cause), objective response rate ([ORR], the proportion of patients with a documented complete response [CR] or partial response [PR]), toxic effects, and safety.
This study was designed to observe 150 deaths to have a power of 80% and a 2-sided α of 10% to detect a 35% reduction in the continuous risk of death. This assumption translated to a hazard ratio (HR) of 0.65, and corresponded to an increase of the median OS from 4.5 months for BSC to 6.9 months for the treatment group. It was calculated that 180 patients had to be enrolled over 18 months and followed for 6 months to observe the required number of deaths.
Overall survival and PFS were analyzed according to intention-to-treat. They were summarized by Kaplan-Meier method, and compared by a stratified log-rank test adjusting for ECOG performance status and site of the primary tumor. The HRs and 90% CIs were calculated based on a stratified Cox proportional hazard model. A Cochran-Mantel-Haenszel test was used to compare ORR between the 2 study groups adjusting for ECOG Performance Status and site of the primary tumor. Adverse events were analyzed according to treatment received and compared by Fisher exact tests among patients who received at least 1 dose of protocol treatments. Data were analyzed on October 18, 2018, and SAS statistical software (version 9.0; SAS Institute, Inc) was used for analysis.
In an exploratory analysis, a minimum P value approach was used to derive an optimal threshold for TMB as a predictive biomarker. This derived threshold was assessed as a predictive biomarker for OS benefit using a test of interaction between treatment group and TMB status in a Cox model.
The CCTG Data and Safety Monitoring Committee regularly evaluated the conduct and safety of the study. The CCTG central office performed randomization, study monitoring, and data verification. Durvalumab and tremelimumab were supplied by MedImmune/AstraZeneca.
Between August 2016 and June 2017, 180 patients were randomized, with 119 patients assigned to the treatment group and 61 patients to BSC alone. One patient did not receive durvalumab and tremelimumab as assigned; this patient was included in the treatment group for efficacy analysis but not in the safety analysis (Figure 1).
Baseline demographics are shown in Table 1. There were slightly higher proportions of female and Asian patients in the treatment group. There were no differences for presence of liver metastases or sidedness. All patients had received multiple lines of prior chemotherapy; 180 (100%) received at least 1 prior chemotherapy for advanced disease containing a fluoropyrimidine, 176 (98%) irinotecan, 154 (86%) oxaliplatin, 143 (79%) had received bevacizumab, and 47 (26%) regorafenib; 68 (97%) of patients with RAS wild-type tumors received cetuximab or panitumumab. No patients had received TAS-102 (trifluridine/tipiracil) during the enrollment period of this study.
Quiz Ref IDPatients in the treatment group received a median of 12 weeks of durvalumab (range, 4-84 weeks) and 12 weeks of tremelimumab (range, 4-24 weeks). Dose reduction or delay as management of adverse events was not permitted per design; however, at least 1 dose omission occurred in 50 (42.4%) patients for durvalumab and 38 (32.2%) for tremelimumab, with the most frequent reasons being investigator decision and hospitalization. In total, 102 (86.4%) and 104 (88.1%) patients received at least 90% of planned durvalumab and tremelimumab doses, respectively.
After disease progression, 8 (6.8%) and 4 (3.4%) patients in the treatment group received TAS-102 and regorafenib, whereas 3 (4.9%) patients in the BSC group received TAS-102. No patients in either groups received immune checkpoint inhibitors postprogression.
Of 180 patients enrolled, baseline blood samples were available in 169 patients (93.9%), and cfDNA analysis was successful in 168 (eTable 1 in Supplement 2). There were 2 patients with MSI-H detected in plasma, 1 in each study group. All 11 missing baseline blood samples were for patients from the BSC group, and 9 of 11 were MSS by tissue-based PCR assessment with 2 unknowns owing to a lack of tissue. There was a higher proportion of patients with KRAS mutation in the treatment group based on cfDNA.
At a median follow-up of 15.2 months (range, 0.16-22.0 months), 154 deaths were observed, with 149 patients (97%) dying due to disease progression. Quiz Ref IDThe median OS was 6.6 months for the treatment group (90% CI, 6.0-7.4 months) and 4.1 months for BSC (90% CI, 3.3-6.0 months). The HR for death was 0.72 (90% CI, 0.54-0.97; P = .07) (Figure 2A). In patients with MSS/pMMR tumors, the HR for death was 0.66 (90% CI, 0.48-0.89; P = .02) (Figure 2B).
The median PFS was 1.8 months in the treatment group (90% CI, 1.8-1.9 months), and 1.9 months in the BSC alone group (90% CI, 1.8-1.9) (eFigure 3 in Supplement 2). The HR for progression was 1.01 (90% CI, 0.76-1.34; P = .97).
There was no CR. One patient with MSS tumors in the treatment group had a PR that lasted longer than 21 months. Stable disease (SD) as the best response was observed in 26 (21.8%) patients of the treatment group and 4 (6.6%) patients in the BSC group. Disease control (CR, PR, or SD) was seen in 27 (22.7%) and 4 (6.6%) of patients in the treatment group and BSC, respectively (odds ratio, 4.16; 90% CI, 1.40-12.3; P = .006).
Plasma TMB was available for 165 patients based on baseline cfDNA. Excluding the 2 cases of MSI-H (TMB 74.7 and 247.1 vts/Mb), the median TMB was 15.3 (range, 0.96-85.4) in the treatment group and 20.9 (range, 1.9-114.9) for the BSC group, respectively (P = .07). Quiz Ref IDPatients with TMB of 28 or more (35 of 163 MSS cases [21%]) had the greatest OS benefit (HR, 0.34; 90% CI, 0.18-0.63; P = .004) for the treatment group (interaction P = .07) (eFigures 1 and 2 in Supplement 2). Quiz Ref IDIn addition, high TMB was associated with a worse OS in the BSC group (HR, 2.59; 90% CI, 1.46-4.62; P = .007).
Adverse events were assessed in 118 patients who received at least 1 study treatment and 61 patients in the BSC group. All patients in the treatment group experienced adverse events, and 75 (62%) had at least 1 grade 3 or higher adverse event, whereas 52 (85%) of patients in the BSC group experienced adverse events, and 12 (20%) had at least 1 grade 3 or higher adverse event (P < .001 (Table 2). Incidences of all grades were significantly higher in the treatment group for fatigue, nausea, constipation, insomnia, cough, diarrhea, and cutaneous eruption. However, grade 3 or higher adverse events were only higher for abdominal pain (P = .05) and fatigue (P = .06).
Incidences of all grades of laboratory abnormalities were significantly higher for lymphopenia, hypoalbuminemia, and hyponatremia in the treatment group, but there was no increase in grade 3 or higher incidences except a borderline higher incidence of lymphopenia. The incidence of TSH elevation of at least 2 × ULN (upper limit of normal) was significantly higher in the treatment group (18% vs 2%, P = .02), and 11 (9%) patients in the treatment group had grade 1 and/or 2 hypothyroidism compared with 1 (2%) in the BSC group. No increased incidences in other immune-mediated adverse events were observed.
Treatment with durvalumab and tremelimumab did not result in significant deterioration in physical function or global health status at 8 weeks or 16 weeks. Details of quality-of-life analysis will be reported separately.
One novel aspect of this study is that cfDNA analysis was successfully incorporated into a colorectal cancer study to interrogate novel predictors of immunotherapy benefit. Baseline blood samples were collected for 169 (94%) of 180 patients enrolled, and cfDNA analysis was successful in 168 of 169 patients. The median TMB in patients with MSS tumors was 16.3 (95% CI, 14.4-20.1). Further analysis revealed that the subclonal TMB (defined as those with variant allele frequency <10% of the maximal allele frequency) accounted for a substantial portion of the total TMB.18 The median clonal TMB was 5.8 (95% CI, 4.8-5.8), similar to the median TMB of 6 (range, 0-361) in MSS advanced colorectal cancer based on next-generation sequencing of primary tumor DNA.19 In a recent study, George et al20 reported that 424 of 1934 (21.9%) patients with MSS tumors had TMB ranging from 8.8 to 43.1. The higher TMB observed in this study may be explained by the fact that patients enrolled underwent multiple lines of systemic therapy, leading to clonal evolution and changes in the variational landscapes that may not present in the primary tumor DNA.21 The rate of KRAS and NRAS variation was 64% and 2% based on tissue analysis, and 78% and 10% based on cfDNA analysis (eTable 1 in Supplement 2). This hypothesis is supported by the observation that the development of resistance to EGFR inhibition is associated with downregulation of mismatch and homologous recombination repair proteins resulting in error-prone DNA repair and increased tumor variagenic ability.22
Tumor variation burden has emerged as a potential biomarker for response to immune checkpoint blockade. High TMB is consistently associated with benefit from immune checkpoint blockade across different types of malignant diseases, such as melanoma, lung, and bladder cancers.21,23-25 A TMB of 28 or more was found to be the optimal threshold as a potential biomarker. Patients with TMB of 28 or more receiving BSC alone had worse OS compared with those with a TMB of less than 28 receiving BSC (median OS, 3.0 vs 5.3 months; P = .007). As seen in eFigure 1A in Supplement 2, the HR fell gradually after a TMB of 20 until reaching a plateau. The statistical power was then gradually eroded above a TMB of 36, by which point most patients fell in the TMB less than 36 group. Similarly, the interaction P value stayed suppressed over an entire range of thresholds above the cut point (eFigure 1B in Supplement 2) until there were limited numbers of patients remaining in the high-TMB group, suggesting this is a real biologic phenomena and not statistical chance.
When treated with durvalumab plus tremelimumab, patients with a TMB of 28 or higher achieved significant survival improvements compared with those receiving BSC alone (median OS, 5.5 vs 3.0 months; P = .004). It is possible that this improvement was owing to the inferior outcome of patients receiving BSC. An interaction test showed a P value of .07, indicating a possible interaction between TMB and treatment with durvalumab and tremelimumab. Those with TMB of 28 or more represented 35 (21%) patients enrolled in this study. Similar benefits were observed based on clonal and subclonal TMB analysis.18 Samstein et al26 reported that the highest 20% of patients with TMB derived better OS from treatment with immune checkpoint inhibitors across different types of cancers. In colorectal cancer, a cutoff value of 52.2 was used, which was the highest among different cancers. The variable responses to immune checkpoint inhibitors in MSI-H colorectal cancer have been attributed to different variational loads among these patients.27,28 Peters et al29 recently presented blood and tissue TMB analysis from a phase 3 study of first-line durvalumab plus tremelimumab vs chemotherapy in patients with metastatic non–small cell lung cancer. Based on cfDNA, 26% patients had TMB of 20 or more. Treatment with durvalumab and tremelimumab was associated with significantly improved PFS and OS compared with chemotherapy in these patients. These data suggest that TMB is a potential biomarker for response to immune checkpoint inhibitors in advanced cancer regardless of MSI status. Genomic analysis of archival tumor tissues and serial blood samples collected while receiving treatment are ongoing.
Like other studies in advanced refractory colorectal cancer,5,6 PFS was short, 1.8 months in the treatment group and 1.9 months in the BSC group. Grothey et al5 reported a median PFS of 1.9 months in patients treated with regorafenib and 1.7 months in the placebo group. Mayer et al6 reported a median PFS of 2.0 months with TAS-102 and 1.7 months in the placebo group. The short PFS in this patient population and the smaller number of patients in this study (180 patients vs 760 and 800 patients in the other 2 studies, respectively) may explain why a significant benefit in OS was seen although there was no apparent improvement in PFS.
Although single-agent immune checkpoint inhibition has not shown meaningful clinical activity in MSS colorectal cancer, emerging data indicate that combining these agents with others with different mechanisms of action can potentially overcome resistance. Fukuoka et al30 reported a response rate of 29% in refractory MSS colorectal cancer with regorafenib and nivolumab. Combining atezolizumab with capecitabine and bevacizumab resulted in increased PFS in refractory MSS colorectal cancer.31 The results of this study further lend support to this strategy.
Patients in the treatment group experienced more frequent adverse events, including more frequent grade 3 or 4 adverse events. In the treatment group, 75 (64%) patients experienced at least 1 grade 3 or higher adverse event, whereas only 12 (20%) patients experienced at least 1 grade 3 or higher adverse event in the BSC group. No new safety concerns were identified. In addition, there was no significant deterioration in physical function or global health status at 8 weeks or 16 weeks.
All 11 patients with missing baseline blood samples were from the BSC group. Although the collection of baseline blood samples was mandated per protocol, collection was permitted after randomization but before commencement of study therapy. It is likely that these patients did not wish to undergo blood collection because of disappointments with treatment assignments. Most of these patients (9 of 11) were subsequently confirmed to be MSS based on analysis of archival tissues. The effect of these missing baseline blood samples on interpretation of our study finding is minimal.
Other important differences between study groups include higher proportions of women (P = .046) and Asians (P = .099) in the treatment group, more patients with BRAF variations (P = .13) and fewer postprogression therapies (P = .25) in the BSC group. These features may favor the treatment group and need to be considered when interpreting our results.
This randomized phase 2 study suggests that combined PD-L1 and CTLA-4 blockade with durvalumab and tremelimumab may prolong OS in patients with heavily pretreated MSS colorectal cancer. Exploratory analysis suggests that TMB from cfDNA analysis could be a potential biomarker for benefits from immune checkpoint inhibitors. Given the lack of treatment options for this patient population, confirmation studies for combined immune checkpoint inhibitors are warranted.
Corresponding Author: Eric X. Chen, MD, PhD, Princess Margaret Cancer Center, 700 University Ave, Rm 7-824, Toronto, ON M5G 1X6 Canada (email@example.com).
Accepted for Publication: March 2, 2020.
Published Online: May 7, 2020. doi:10.1001/jamaoncol.2020.0910
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Chen EX et al. JAMA Oncology.
Author Contributions: Drs Chen and O’Callaghan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Chen, Jonker, Loree, Ahmad, Kavan, Tu, O'Callaghan.
Acquisition, analysis, or interpretation of data: Chen, Jonker, Loree, Kennecke, Berry, Couture, Goffin, Kavan, Harb, Colwell, Samimi, Samson, Abbas, Aucoin, Aubin, Koski, Wei, Magoski, Tu, O'Callaghan.
Drafting of the manuscript: Chen, Jonker, Loree, Ahmad, Kavan, Abbas.
Critical revision of the manuscript for important intellectual content: Chen, Jonker, Loree, Kennecke, Berry, Couture, Goffin, Kavan, Harb, Colwell, Samimi, Samson, Aucoin, Aubin, Koski, Wei, Magoski, Tu, O'Callaghan.
Statistical analysis: Loree, Tu, O'Callaghan.
Obtained funding: Jonker, Aucoin, O'Callaghan.
Administrative, technical, or material support: Chen, Jonker, Loree, Kennecke, Couture, Goffin, Samimi, Aucoin, Aubin, Wei, Magoski, O'Callaghan.
Supervision: Jonker, Ahmad, Kavan, Samimi, Abbas, Aubin, Koski, O'Callaghan.
Conflict of Interest Disclosures: Dr Chen participated in clinical trials sponsored by Merck, BMS, Boston Biomedical, AZ, and received research support (drugs only) from AZ. Dr Chen received honoraria from Eisai and Taiho. Dr Loree received research support from Ipsen and honoraria from Ipsen, Amgen, Bayer, Novartis, and Taiho. Dr Samson received honorarium from Taiho. Dr Goffin received honoraria from Merck and Amgen and nonfinancial support from AZ. Dr Samimi received honoraria from Amgen, Celgene, Ipsen, Apobiologix, Eisai, Taiho, and Roche. Dr Aubin received honoraria from Taiho, Shire, Amgen, BMS, and Celgene, and participated in clinical trials sponsored by Merck and BMS. Dr Aucoin received honoraria from AZ, Roche, BMS, Amgen, Takeda, Pfizer, Taiho, Celgene. Dr Wei received honoraria from Shire and Celgene, and nonfinancial support from Bayer. All other authors declared no competing interests.
Data Sharing Statement: See Supplement 3.
Funding/Support: AstraZeneca provided durvalumab and tremelimumab and contributed partial funding for this study. The Canadian Cancer Trials Group (CCTG) is funded by the Canadian Cancer Society.
Role of the Funder/Sponsor: AstraZeneca was consulted on design of the study, and reviewed a draft of the manuscript. It played no role in conduct of the study; collection, management, analysis, and interpretation of the data; preparation, or approval of the manuscript; and decision to submit the manuscript for publication.
Meeting Presentation: Presented at ASCO GI Symposium, January 19, 2019, San Francisco, California; and at ASCO Annual Meeting, June 3, 2019, Chicago, Illinois.
Create a personal account or sign in to: